The Role of Risk Analysis in Expanding Business Activities - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Role of Risk Analysis in Expanding Business Activities
Risk management is essential in any successful outsourcing partnership. The author outlines the steps toward identifying, understanding, and controlling risk in key manufacturing areas.


Pharmaceutical Technology


Main risk areas

The following are examples of major risk areas:

  • Absence of a reference person or reduced professional competence. If the sponsor does not have a stable and competent reference person from the service provider tocollect and discuss the troubles, the company cannot obtain the interdisciplinary supplier evaluation that is often needed in this kind of partnership.
  • Inadequate equipment (e.g., inappropriate scale-up equipment)
  • Old equipment or bad maintenance
  • Absence of backup or contingency procedures
  • Difficulty establishing the transformation's costs (e.g., supplier ignorance of the goods and industrial formulation costs, resulting in price variance after the contract is signed)
  • Lack of structure or procedures (e.g., personnel experience, culture, and structure).

Check audit

The evaluation questionnaire alone is not enough. Several inspective checks should be conducted before considering the risk and defining the action plan. If the sponsor company wants to know in detail the status of the service provider's capability, more than one audit should be conducted, particularly in the main areas considered critical for business continuity. Focused checks in the critical areas help to better define the risk and the subsequent remediation plan.

It is also essential, when the action plan has been defined, that the sponsor company monitor the carrying out of the interventions contemplated in the action plan and that the partner be reliable and transparent when executing the plan.

The corrective actions defined in the remediation plan must be realized in a defined timeframe and as requested. Any problem during the advancement of this action plan could postpone the project start and have a negative, and sometimes disastrous, effect on business.

Maurizio Battistini is general manager of APP Pharmaceutical Partners Switzerland GmbH, Via Cadepiano, 24 CH-6917 Barbengo, Switzerland,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here